دورية أكاديمية
أعرض في EDS

Development of Small-Molecule STING Activators for Cancer Immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Development of Small-Molecule STING Activators for Cancer Immunotherapy.
المؤلفون: Jung HR; Creative Research Center for Brain Science, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.; Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea., Jo S; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.; Department of Pharmacy, College of Pharmacy, Chungnam National University, Daejeon 34134, Korea., Jeon MJ; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea.; Department of Medicinal Chemistry and Pharmacology, University of Science & Technology, Daejeon 34113, Korea., Lee H; Creative Research Center for Brain Science, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.; Department of Pharmacy, College of Pharmacy, Kyung Hee University, Seoul 02447, Korea., Chu Y; Creative Research Center for Brain Science, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.; Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea., Lee J; Creative Research Center for Brain Science, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.; Department of HY-KIST Bio-Convergence, Hanyang University, Seoul 04763, Korea., Kim E; Department of Molecular Science and Technology, Ajou University, Suwon 16499, Korea., Song GY; Department of Pharmacy, College of Pharmacy, Chungnam National University, Daejeon 34134, Korea., Jung C; Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Korea., Kim H; Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon 34114, Korea., Lee S; Creative Research Center for Brain Science, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Korea.; Department of HY-KIST Bio-Convergence, Hanyang University, Seoul 04763, Korea.
المصدر: Biomedicines [Biomedicines] 2021 Dec 24; Vol. 10 (1). Date of Electronic Publication: 2021 Dec 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: In cancer immunotherapy, the cyclic GMP-AMP synthase-stimulator of interferon genes (STING) pathway is an attractive target for switching the tumor immunophenotype from 'cold' to 'hot' through the activation of the type I interferon response. To develop a new chemical entity for STING activator to improve cyclic GMP-AMP (cGAMP)-induced innate immune response, we identified KAS-08 via the structural modification of DW2282, which was previously reported as an anti-cancer agent with an unknown mechanism. Further investigation revealed that direct STING binding or the enhanced phosphorylation of STING and downstream effectors were responsible for DW2282-or KAS-08-mediated STING activity. Furthermore, KAS-08 was validated as an effective STING pathway activator in vitro and in vivo. The synergistic effect of cGAMP-mediated immunity and efficient anti-cancer effects successfully demonstrated the therapeutic potential of KAS-08 for combination therapy in cancer treatment.
References: Cell Rep. 2015 May 19;11(7):1018-30. (PMID: 25959818)
Acta Pharm Sin B. 2020 Dec;10(12):2272-2298. (PMID: 33354501)
Invest New Drugs. 1993 Feb;11(1):87-90. (PMID: 8394298)
Nature. 2018 Dec;564(7736):439-443. (PMID: 30405246)
J Immunother Cancer. 2019 Feb 13;7(1):46. (PMID: 30760319)
Biomed Pharmacother. 2021 Jan;133:110972. (PMID: 33254021)
J Clin Med. 2020 Oct 16;9(10):. (PMID: 33081170)
J Med Chem. 1990 Sep;33(9):2393-407. (PMID: 2391684)
Sci Transl Med. 2020 Jun 24;12(549):. (PMID: 32581136)
Mol Cell. 2013 Jul 25;51(2):226-35. (PMID: 23747010)
Nature. 2008 Oct 2;455(7213):674-8. (PMID: 18724357)
J Hematol Oncol. 2019 Apr 1;12(1):35. (PMID: 30935414)
Bioorg Med Chem. 2011 Jan 1;19(1):287-94. (PMID: 21131205)
Cancer Cell. 2015 Apr 13;27(4):450-61. (PMID: 25858804)
Viruses. 2019 Mar 12;11(3):. (PMID: 30871003)
Biochem Pharmacol. 2002 Aug 1;64(3):473-80. (PMID: 12147299)
BMC Genomics. 2014 Mar 13;15:190. (PMID: 24621249)
J Exp Med. 2011 Sep 26;208(10):1989-2003. (PMID: 21930769)
Immunity. 2006 Jan;24(1):93-103. (PMID: 16413926)
Cancer Res. 2009 Apr 1;69(7):3077-85. (PMID: 19293190)
Nat Cancer. 2020 Feb;1(2):184-196. (PMID: 33768207)
ACS Chem Biol. 2013 Jul 19;8(7):1396-401. (PMID: 23683494)
Science. 2015 Mar 13;347(6227):aaa2630. (PMID: 25636800)
Biochem Pharmacol. 2001 Dec 1;62(11):1439-47. (PMID: 11728380)
J Exp Med. 2011 Sep 26;208(10):2005-16. (PMID: 21930765)
Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. (PMID: 30540940)
FASEB J. 2020 Oct;34(10):13156-13170. (PMID: 32860267)
Curr Opin Immunol. 2014 Dec;31:121-6. (PMID: 25459004)
ACS Chem Biol. 2018 Feb 16;13(2):366-375. (PMID: 29261286)
Cell. 2013 Aug 15;154(4):748-62. (PMID: 23910378)
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11946-11955. (PMID: 31142647)
Nat Chem Biol. 2014 Aug;10(8):623-5. (PMID: 24929529)
Nature. 2019 May;569(7758):718-722. (PMID: 31118511)
Vaccines (Basel). 2020 Aug 13;8(3):. (PMID: 32823563)
Anticancer Res. 1999 Nov-Dec;19(6B):5087-93. (PMID: 10697515)
JAMA Netw Open. 2019 May 3;2(5):e192535. (PMID: 31050774)
Front Immunol. 2021 Apr 01;12:660184. (PMID: 33868310)
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9. (PMID: 25071169)
Cell Chem Biol. 2020 Nov 19;27(11):1347-1358.e5. (PMID: 32726585)
Cancer Lett. 1999 Jun 1;140(1-2):177-87. (PMID: 10403557)
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. (PMID: 26607445)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1637-1642. (PMID: 28137885)
Front Oncol. 2018 Mar 28;8:86. (PMID: 29644214)
Cell Rep. 2020 Apr 7;31(1):107492. (PMID: 32268090)
Science. 2020 Aug 21;369(6506):. (PMID: 32820094)
Cancer Discov. 2020 Mar;10(3):382-393. (PMID: 31974171)
Nature. 2019 Mar;567(7748):394-398. (PMID: 30842653)
معلومات مُعتمدة: 2E30952, 2E30956 Korea Institute of Science and Technology; KK2032-00 Korea Research Institute of Chemical Technology; 2019M3E5D4066905, 2020R1C1C1003736, 2021R1C1C1005134 National Research Foundation of Korea
فهرسة مساهمة: Keywords: STING; STING activator; cancer immunotherapy; type I interferon
تواريخ الأحداث: Date Created: 20220121 Latest Revision: 20220128
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8773171
DOI: 10.3390/biomedicines10010033
PMID: 35052713
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines10010033